Antitussive offers convenient twice-daily dosing

News
Article

The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
Related Content
FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Killian Meara
July 10th 2025
Article

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Ashley Gallagher
June 24th 2025
Article

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Ashley Gallagher
June 20th 2025
Article

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.

FDA Approves Nitisinone for Treatment of Alkaptonuria

FDA Approves Nitisinone for Treatment of Alkaptonuria

Ashley Gallagher
June 19th 2025
Article

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

Ashley Gallagher
June 2nd 2025
Article

The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.

© 2025 MJH Life Sciences

All rights reserved.